Cannara Biotech Inc.

LOVE

CA13765U2002

Healthcare Facilities & Services

Delayed Toronto S.E. Other stock markets 15:57:29 16/07/2024 BST			5-day change	1st Jan Change
0.63 ^CAD	+1.61%		-4.55%	-24.10%

04-29	Cannara Biotech Turns Negative As Reports Wider Q2 Net Loss Vs a Year Ago, Despite Revenue up 51%	MT
04-29	Tranche Update on Cannara Biotech Inc.'s Equity Buyback Plan announced on November 30, 2022.	CI

Cannara Biotech Inc. Announces Revenues Results for the Three-Month Period Ended November 30, 2018

January 29, 2019 at 12:54 pm

Cannara Biotech Inc. announced revenues results for the three-month period ended November 30, 2018. For the quarter, the company reported revenue from short-term leases of $518,443.

Latest news about Cannara Biotech Inc.

Cannara Biotech Turns Negative As Reports Wider Q2 Net Loss Vs a Year Ago, Despite Revenue up 51%	04-29	MT
Tranche Update on Cannara Biotech Inc.'s Equity Buyback Plan announced on November 30, 2022.	04-29	CI
Cannara Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024	04-29	CI
Tranche Update on Cannara Biotech Inc.'s Equity Buyback Plan announced on November 30, 2022.	01-29	CI
Cannara Biotech Inc. Reports Earnings Results for the First Quarter Ended November 30, 2023	01-29	CI
Tranche Update on Cannara Biotech Inc.'s Equity Buyback Plan announced on November 30, 2022.	12-07	CI
Cannara Biotech Inc. Reports Earnings Results for the Full Year Ended August 31, 2023	12-07	CI
Cannara Biotech's Fiscal Q4 Profit, Revenue Grows; Up 9.4%	12-07	MT
Cannara Biotech Inc. Reports Earnings Results for the Fourth Quarter Ended August 31, 2023	12-07	CI
Tranche Update on Cannara Biotech Inc.'s Equity Buyback Plan announced on November 30, 2022.	27/07/23	CI
Cannara Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023	27/07/23	CI
Tranche Update on Cannara Biotech Inc.'s Equity Buyback Plan announced on November 30, 2022.	24/04/23	CI
Cannara Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2023	24/04/23	CI
Cannara Biotech Down Near 8% As Enters into an Automatic Share Purchase Plan	28/02/23	MT
Cannara Biotech Converts CA$5 Million Debenture, Plus Interest, into Nearly 30 Million Shares for Olymbec Investments	10/02/23	MT
Tranche Update on Cannara Biotech Inc.'s Equity Buyback Plan announced on November 30, 2022.	23/01/23	CI
Cannara Biotech Inc. Reports Earnings Results for the First Quarter Ended November 30, 2022	23/01/23	CI
Cannara Biotech Reports Normal Course Issuer Bid for Common Shares	30/11/22	MT
Cannara Biotech Inc. announces an Equity Buyback for 15,000,000 shares, representing 1.71% of its issued share capital.	30/11/22	CI
Toronto Stocks Rise, Cannara Biotech Shares Climb on 4Q Results	25/11/22	DJ
Cannara Biotech Gains 5% as Q4 EPS Unchanged at $0.01 Vs Year Ago; Revenue $11.9 Million Vs $6.5 Million	25/11/22	MT
Cannara Biotech Q4 EPS Unchanged at $0.01 Vs Year Ago; Revenue $11.9 Million Vs $6.5 Million	25/11/22	MT
Cannara Biotech Inc. Reports Earnings Results for the Full Year Ended August 31, 2022	25/11/22	CI
Cannara Biotech Inc. authorizes a Buyback Plan.	10/11/22	CI
Cannara Releasing 14 SKUs Across Ontario, Quebec Under Tribal, Nugz, and Orchid CBD Brands	30/09/22	MT

Cannara Biotech Inc. is a Canada-based vertically integrated producer of premium-grade cannabis and cannabis-derivative products for the Quebec and Canadian markets. It operates through its wholly owned subsidiaries, Cannara Biotech (Quebec) Inc. and Cannara Biotech (Valleyfield) Inc. The Company owns two mega facilities based in Quebec spanning over 1,650,000 square feet, providing the Company with 100,000 kilograms of annualized cultivation output. It operates in two segments: Cannabis operations and Real estate operations. The Cannabis operations, which encompasses the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and other cannabis services (Cannabis operations). The Real estate operations, related to the Farnham and Valleyfield building (Real estate operations). The Companyâs brand portfolio includes Tribal, Nugz, and Orchid CBD. Orchid CBD is a wellness brand that provides premium CBD-dominant cannabis.

Sector

Healthcare Facilities & Services

Calendar

24/07/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Medical Farming

	1st Jan change	Capi.
CANNARA BIOTECH INC.	-24.10%	40.85M
AYR WELLNESS INC.	+19.75%	228M
ORGANIGRAM HOLDINGS INC.	+38.66%	177M
ASCEND WELLNESS HOLDINGS, INC.	-14.43%	173M
BAKHU HOLDINGS, CORP.	+270.00%	121M
JUSHI HOLDINGS INC.	+31.11%	112M
INTERCURE LTD.	+88.45%	109M
THE CANNABIST COMPANY HOLDINGS INC.	-51.20%	98.86M
IANTHUS CAPITAL HOLDINGS, INC.	-28.57%	97M
4FRONT VENTURES CORP.	+7.69%	80.38M